Compare Alcon AG (ALC) vs Allstate Corp (ALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Allstate Corp — how do they compare? Alcon AG trades at $75 (market cap $36.44B), while Allstate Corp trades at $256.21 (market cap $66.31B). The key difference: Allstate Corp is the larger of the two by market cap, and Allstate Corp pays the higher dividend (1.65%). Which is the better fit depends on your goals.
| ALC | ALL | |
|---|---|---|
Market Cap | $36.44B | $66.31B |
Sector | Health | Financials |
52-Week High | $90.12 | $275.11 |
52-Week Low | $62.02 | $190.00 |
Enterprise Value | $40.28B | $74.96B |
Dividend Yield | 0.48% | 1.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.59, down slightly by 0.05% today, with a bullish technical signal from moving averages and a consensus analyst price target of $86.67 implying 17.8% upside. Recent Q2 2026 earnings beat estimates with EPS of $0.84 versus $0.77 expected, and the company raised its 2026 profitability outlook, driving positive investor sentiment. Revenue growth has been steady, reaching $10.40 billion in 2025, though net income margin dipped to 5.92%.
The outlook is positive given strong earnings beats, raised guidance, and bullish analyst ratings, but risks include elevated P/E of 57.52, high RSI levels suggesting overbought conditions, and margin pressures from rising costs. Institutional ownership trends and recent collaborations, like with RxSight, support growth, yet macroeconomic and competitive factors warrant caution.
Allstate (ALL) trades at $256.24, down 4.98% on the day, but remains near recent highs with strong technical support at $253. The company reported robust Q2 2026 earnings of $8.99 per share, beating estimates, driven by improved underwriting and investment income. Revenue growth has accelerated from $51.4B in 2022 to $67.1B in 2025, with net income margin expanding to 19.19%. Analyst consensus is a Buy with a $266.47 price target, though sentiment is mixed on sustainability of peak profitability.
Outlook is positive given earnings momentum and attractive valuation (P/E 5.25), but risks include potential normalization of underwriting margins and macroeconomic sensitivity. The stock offers value with high ROE (49.11%) and consistent dividend payments, yet investors should weigh cyclical insurance pressures against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →
